Patents by Inventor MICHAEL LUTTEROPP

MICHAEL LUTTEROPP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form
    Patent number: 11883494
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: January 30, 2024
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form
    Publication number: 20230248823
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Application
    Filed: March 20, 2023
    Publication date: August 10, 2023
    Applicant: MILTENYI BIOTEC B.V .& CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells
    Patent number: 11419935
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: August 23, 2022
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • IMMUNOTHERAPY METHOD COMPRISING ADMINISTERING A COMBINATION OF IMMUNE EFFECTOR CELLS AND NON-TARGET HEMATOPOIETIC CELLS
    Publication number: 20210401980
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Applicant: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • COMBINATION OF IMMUNE EFFECTOR CELLS SPECIFIC FOR A TARGET ANTIGEN AND HEMATOPOIETIC CELLS THAT EXPRESS THE TARGET ANTIGEN IN AN ALTERED FORM
    Publication number: 20210338814
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 4, 2021
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
    Patent number: 11033619
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 15, 2021
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
    Patent number: 10201606
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: February 12, 2019
    Assignee: MILTENYI BIOTEC GMBH
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
    Publication number: 20180280502
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 4, 2018
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
    Publication number: 20160144026
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Application
    Filed: November 25, 2015
    Publication date: May 26, 2016
    Inventors: MICHAEL LUTTEROPP, ANNE RICHTER, ANDREW KAISER, MARIO ASSENMACHER, STEFAN MILTENYI